Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SIFY
3026
Sify Technologies
SIFY
$1.15B
| $165K | ﹤0.01% |
38,717
+1,800
| +5% | +$8.99K |
|
3027
W&T Offshore
WTI
$546M
| $164K | ﹤0.01% |
+83,600
| New | +$182K |
|
3028
InfuSystem Holdings
INFU
$249M
| $163K | ﹤0.01% |
93,000
+4,400
| +5% | +$7.93K |
|
3029
Teekay
TK
$1.06B
| $163K | ﹤0.01% |
24,500
-331,800
| -93% | -$2.45M |
|
|
AIFC
3030
AI Financial Corp
AIFC
$58.9M
| $162K | ﹤0.01% |
40,980
+900
| +2% | +$3.8K |
|
|
ATXS
3031
DELISTED
Astria Therapeutics
ATXS
| $161K | ﹤0.01% |
1,908
+806
| +73% | +$67.1K |
|
|
TORM
3032
DELISTED
TOR Minerals International Inc
TORM
| $161K | ﹤0.01% |
20,000
+2,000
| +11% | +$15.3K |
|
|
EMITF
3033
DELISTED
Elbit Imaging Ltd
EMITF
| $159K | ﹤0.01% |
54,413
+700
| +1% | +$2.27K |
|
3034
Indaptus Therapeutics
INDP
$141M
| $154K | ﹤0.01% |
12
+6
| +100% | +$72.8K |
|
3035
Barnwell Industries
BRN
$13.9M
| $151K | ﹤0.01% |
83,500
+2,400
| +3% | +$4.57K |
|
3036
Solitario Resources
XPL
$73.9M
| $150K | ﹤0.01% |
223,820
-12,980
| -5% | -$9.63K |
|
|
CTHR
3037
DELISTED
Charles & Colvard Ltd
CTHR
| $150K | ﹤0.01% |
16,290
-820
| -5% | -$7.49K |
|
3038
Ocugen
OCGN
$458M
| $149K | ﹤0.01% |
1,383
+205
| +17% | +$21K |
|
3039
Stabilis Solutions
SLNG
$104M
| $147K | ﹤0.01% |
10,350
+225
| +2% | +$3.02K |
|
|
BAA
3040
DELISTED
Banro Corporation Common Stock
BAA
| $147K | ﹤0.01% |
203,510
-3,240
| -2% | -$3.31K |
|
|
OIG
3041
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
| $144K | ﹤0.01% |
+935
| New | +$147K |
|
3042
Tandem Diabetes Care
TNDM
$1.61B
| $142K | ﹤0.01% |
17,780
+1,140
| +7% | +$10.5K |
|
|
NOTV
3043
DELISTED
Inotiv
NOTV
| $141K | ﹤0.01% |
85,100
+31,400
| +58% | +$46.9K |
|
|
PPSI
3044
Pioneer Power Solutions
PPSI
$33.5M
| $140K | ﹤0.01% |
21,400
-13,200
| -38% | -$89.5K |
|
3045
Enlivex Ltd
ENLV
$28.4M
| $139K | ﹤0.01% |
346
+80
| +30% | +$24.3K |
|
3046
Retractable Technologies
RVP
$20.3M
| $139K | ﹤0.01% |
109,300
+17,700
| +19% | +$18.9K |
|
|
UNAM
3047
DELISTED
Unico American Corp
UNAM
| $139K | ﹤0.01% |
14,900
+500
| +3% | +$4.84K |
|
3048
Taoping
TAOP
$8.83M
| $137K | ﹤0.01% |
81
+9
| +13% | +$14K |
|
3049
Digital Turbine
APPS
$1.53B
| $136K | ﹤0.01% |
131,779
+72,815
| +123% | +$77K |
|
3050
Denison Mines
DNN
$2.95B
| $135K | ﹤0.01% |
313,200
-206,500
| -40% | -$105K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.